Active ingredientSparsentanCat. No. P-S073-001CAS 254740-64-2Family · Pharmaceutical analytical standards
Sparsentan
A dual endothelin and angiotensin II receptor antagonist, approved in 2023 in the United States and in 2024 in Europe to reduce proteinuria in IgA nephropathy, a kidney disease. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It combines two mechanisms in a single molecule and the FDA regards it as a first-in-class medicine; it was first studied for hypertension and diabetic nephropathy.
Go to the active ingredient →Active ingredientSparsentanCat. No. P-S073-001CAS 254740-64-2
Isotopically labelledSparsentan-d5Cat. No. P-S073-002CAS 1801597-09-0
ImpuritySparsentan Impurity 1 (RE-0004090)Cat. No. P-S073-003CAS 254737-96-7
ImpuritySparsentan Impurity 2 (RE-0004095)Cat. No. P-S073-004CAS 1399412-15-7
ImpuritySparsentan Impurity 3 (RE-0004091)Cat. No. P-S073-005No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.